News and Trends 12 Jan 2016
Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled
Cellectis researchers have managed to come up with a new CAR architecture with a small-molecule triggered ‘on-switch’, permitting better control and safety in CAR T-cell therapy, as published in Nature. As we discussed during our interview with Andre Choulika, CEO of Cellectis, last month, one major drawback to CAR-T treatment for cancer is the lack of […]